ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: SA-PO900

Treatment of IgA Nephropathy in Chinese Patients: Evidence from Real-World Data

Session Information

Category: Glomerular Diseases

  • 1402 Glomerular Diseases: Clinical, Outcomes, and Trials

Authors

  • Wang, Weiming, Shanghai Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
  • Li, Runqin, Beijing Novartis Pharma. Co. Ltd., Shanghai, China
  • Li, Ping, Beijing Novartis Pharma. Co. Ltd., Shanghai, China
  • Gao, Fei, Beijing Novartis Pharma. Co. Ltd., Shanghai, China
  • Smeets, Serge, Novartis Pharma AG, Basel, Switzerland
  • George, Aneesh T., Novartis Healthcare Private Limited, Hyderabad, India
  • de Courcy, Jonathan, Adelphi Real World, Bollington, United Kingdom
Background

Immunoglobulin A nephropathy (IgAN) accounts for more than 50% of primary glomerulonephritis in China1. The aim of this real-world study was to describe and compare the treatment strategy of Chinese nephrologist with nephrologists across the world for patients with IgAN.

Methods

A point-in-time, cross-sectional survey utilizing data from Adelphi Real-world IgAN Disease-Specific Programme was conducted in China, Japan, United States (US) and Europe (EU5: France, Germany, Italy, Spain, United Kingdom), from June to October 2021. 60 nephrologists from China completed a structured online record for successive 587 IgAN patients, including treatment regimens and patient clinical characteristics.

Results

The proportion of different lines of treatments with ACEi/ARB, SGLT2i, corticosteroids and other therapy was analyzed and shown (Figure 1). Compared with EU5 and US, the proportion of ACEi/ARB use at first line was lower in Asia (EU5 84%, US 86%, China 74%, Japan 59%), while the use of corticosteroids in Asia as first line was higher (EU5 36%, US 44%, China 47%, Japan 63%). Main reasons to stop corticosteroids was when patient's condition improved, treatment course completed, or side effects, of which weight gain (51%), acne (43%) and insomnia (30%) were most reported by Chinese nephrologists. Despite different lines of treatment, the proteinuria and eGFR levels were not well controlled (Table 1).

Conclusion

Despite attempts to alter various therapeutic regimens, IgAN remained poorly controlled. These data highlight an unmet need for the development of more effective drugs to treat and mitigate disease progression.

Figure 1 Treatment strategies adopted by nephrologists between different line treatments

Table 1 Mean Proteinuria and eGFR levels in patients with different line* treatments

Funding

  • Commercial Support – Novartis Pharma AG